Complex Treatment of Multiple Sclerosis Patients by Use of Fetal StemCells

Objective: Refinement for all existing methods of treatment for the multiple sclerosis patients by means of combined method including conventional therapy and administration of fetal stem cells (FSCs)-suspensions containing stem cells derived from human fetal liver and brain. Materials and methods: 51 patients diagnosed with MS participated in the study including 27 men and 24 women aged 27 to 56 years. Average age range for men was 34.2 ± 1.2 years, for women it constituted 31.7 ± 1.3 years. 33 patients were allocated in the Main Group (MG) including 20 men (mean age 29.8 ± 2.2 years) and 13 women (average age 31.3 ± 2.1 years). The Control Group (CG) was composed of 18 patients diagnosed with MSincluding 10 men (mean age of 30.5 ± 1.2 years) and 8 women (average age 31.4 ± 1.4 years). Simultaneously, the scale of MMSE was applied for objective study of cognitive functions among our patients. State Trait Anxiety Inventory was effective for emotional-anxiety disturbances. In addition, we assessed depression in patients by means of Beck Depression Inventory. Results: Authors proved efficacy and safety of FSCs suspensions for MS patients. We emphasized a significant improvement of neurology deficit in the MG already over 6 months after fetal stem cells transplantation (FSCT), whereas the CG patients revealed such advantages over 12 months. Improvement of cognitive functions was characteristic for the MG starting from 6 months after FSCT. Anxiety and depression significantly decreased and these results were observed over 6 months after FSCT in the MG. In the CG, the same values which significantly decreased over 12 months after treatment and were recorded. Conclusion: FSCs use in complex treatment of patients with MS stabilizes disease compensation, improves cognitive functions as well as psycho-emotional state of the patients.